- Cancer-focused biotech PMV Pharmaceuticals ( NASDAQ: PMVP ) announced an agreement with Merck ( MRK ) on Monday to study its lead product candidate PC14586 in combination with Merck’s ( MRK ) anti-PD-1 therapy Keytruda in advanced solid tumors.
- Accordingly, PMV ( PMVP ) will add a combination arm to study the experimental drug in the company’s ongoing Phase 1/2 PYNNACLE trial for patients with advanced solid tumors.
- The combination arm, designed to assess PC14586/ Keytruda combo in patients with advanced solid tumors harboring a p53 Y220C mutation, is expected to recruit about 36 subjects. Per the terms, PMV Pharma ( PMVP ) will sponsor the study, and Merck ( MRK ) will supply Keytruda.
- PC14586 is an investigational small molecule designed to selectively target the p53 Y220C mutation of cancers.
- Read: PMV ( PMVP ) traded lower last month after the company announced early data from the PYNNACLE trial for PC14586.
For further details see:
PMV Pharma joins Merck to study lead candidate with Keytruda